Stephanie J Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) kindly took the time to discuss with us pooled findings from phase 3 randomised controlled trials with fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treatment, specifically in older patients (≥60 years) with episodic or chronic migraine.
1. How does the clinical phenotype of migraine differ in patients aged 60 and over compared with that in younger patients? (0:05)
2. What are the main unmet needs in the treatment of episodic or chronic migraine in this patient group? (0:57)
3. How extensively has fremanezumab been studied in this patient group? (2:01)
4. What were the efficacy and safety findings of your pooled analysis? (3:00)
5. Among older patients, which are likely to benefit most from fremanezumab and in whom is it contraindicated? (4:46)
Speaker disclosure: Stephanie J Nahas has served on an advisory board, as a speaker, or as a consultant for Allergan, Amgen/Novartis, Biohaven, electroCore, Eli Lilly, Impel, Supernus, Teva Pharmaceuticals, Theranica, and Zosano.
Support: Interview and filming supported by Touch Medical Media.
Filmed at the 6th Congress of the European Academy of Neurology (EAN) and 1st EAN Virtual Congress, May 2020.
Share this Video
Related Videos In Headache Disorders
Serena Orr, AHS 2021: Stress and Peak Pain Severity in Chronic Migraine
We had the great pleasure of meeting with Dr. Serena Orr (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) to discuss the relationship between peak pain severity in chronic migraine, and its relationship to stress. The abstract ‘The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study […]
Jessica Ailani, EAN 2021: Phase 3b CONQUER Trial Results
It was a great pleasure to meet with Jessica Ailani (MedStar Georgetown, Georgetown University Hospital, Pasquerilla Healthcare Center, Washington, WA, USA) to discuss the impact of galcanezumab on migraine care in the phase 3b CONQUER trial. The abstract entitled: ‘Total pain burden in patients with treatment-resistant migraine: effects of galcanezumab in the CONQUER Phase 3b […]
Michael Marmura, AHS 2021: Intranasal Ketamine for the Treatment of Refractory Headache
touchNEUROLOGY met with Michael Marmura (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) to discuss his study investigating intranasal ketamine for the treatment of refractory headache. The abstract ‘Intranasal Ketamine for Refractory Headache’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021. Questions: What is the rationale […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!